Axonics® Announces Survey Results of Patients Treated with the Axonics r-SNM System That Were Previously Implanted with InterStim II
In the survey, Axonics asked patients about Axonics SNM therapy and to make comparisons to their prior experience with InterStim II. Key findings of the survey include:
-
Patients prefer Axonics therapy over InterStim II
- 92% of patients that have been treated with both systems would choose Axonics over InterStim if they were asked to decide about the therapy again
- 83% of patients would recommend Axonics over InterStim to a friend. Only 5% of patients stated they would recommend InterStim over Axonics
- 78% of patients said that the recommendation of their physician was key to their decision to switch
-
Patients that prefer Axonics over InterStim cited the following as the most important features of the Axonics System:
- 15+ year life; fewer repeat procedures
- MRI compatibility
- Easy to use remote control
-
Patients feel they are doing better with Axonics compared to InterStim II
- 71% of patients said they are having a better overall experience with the Axonics System compared to InterStim. Only 11% of patient said they preferred the non-rechargeable InterStim
- 53% of patients are experiencing better symptom relief with Axonics than InterStim, while 38% stated they are experiencing about the same level of symptom relief
-
Patients are finding it easy to recharge the Axonics System and use the patient remote control
- 91% of patients are not bothered by recharging their Axonics System
- 81% of patients stated that recharging the Axonics System is easy despite only having experience with a non-rechargeable implant previously
-
82% of patients rated their Axonics patient remote control experience as “Excellent” or “Good.” Features of the Axonics remote control cited as most beneficial compared to InterStim include:
- Easier to make adjustments to stimulation level
- Easy to check status of stimulation
- Comfortable one-handed use
- Smaller size
Cohen continued, "Delivering a superior experience to patients has been the key focus of our product development initiatives since Axonics’ founding. We remain confident that our keen focus on innovation, enhancing the patient experience, and increasing awareness of SNM therapy will drive significant market expansion in the years ahead."
About
Axonics, based in
View source version on businesswire.com: https://www.businesswire.com/news/home/20201005005188/en/
949-336-5293
IR@axonics.com
Source: